These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 24120954)

  • 1. Multidrug resistance: Physiological principles and nanomedical solutions.
    Kunjachan S; Rychlik B; Storm G; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1852-1865. PubMed ID: 24120954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
    Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using nanotechnology to progress the utilization of marine natural products in combating multidrug resistance in cancer: A prospective strategy.
    Bhusare N; Gade A; Kumar MS
    J Biochem Mol Toxicol; 2024 Jun; 38(6):e23732. PubMed ID: 38769657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance.
    Zhou L; Wang H; Li Y
    Theranostics; 2018; 8(4):1059-1074. PubMed ID: 29463999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano Strategies for Artemisinin Derivatives to Enhance Reverse Efficiency of Multidrug Resistance in Breast Cancer.
    Zhang X; Li N; Zhang G; Li J; Liu Y; Wang M; Ren X
    Curr Pharm Des; 2023; 29(43):3458-3466. PubMed ID: 38270162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotechnology-based delivery systems to overcome drug resistance in cancer.
    Patel H; Li J; Bo L; Mehta R; Ashby CR; Wang S; Cai W; Chen ZS
    Med Rev (2021); 2024 Feb; 4(1):5-30. PubMed ID: 38515777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-viral vectors combined delivery of siRNA and anti-cancer drugs to reverse tumor multidrug resistance.
    Xue R; Pan Y; Xia L; Li J
    Biomed Pharmacother; 2024 Sep; 178():117119. PubMed ID: 39142247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress.
    Ortíz R; Quiñonero F; García-Pinel B; Fuel M; Mesas C; Cabeza L; Melguizo C; Prados J
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33923200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?
    Callaghan R; Luk F; Bebawy M
    Drug Metab Dispos; 2014 Apr; 42(4):623-31. PubMed ID: 24492893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanodrug delivery in reversing multidrug resistance in cancer cells.
    Kapse-Mistry S; Govender T; Srivastava R; Yergeri M
    Front Pharmacol; 2014; 5():159. PubMed ID: 25071577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade.
    Kathawala RJ; Gupta P; Ashby CR; Chen ZS
    Drug Resist Updat; 2015 Jan; 18():1-17. PubMed ID: 25554624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function.
    Sharom FJ
    Front Oncol; 2014; 4():41. PubMed ID: 24624364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The multiple facets of drug resistance: one history, different approaches.
    Niero EL; Rocha-Sales B; Lauand C; Cortez BA; de Souza MM; Rezende-Teixeira P; Urabayashi MS; Martens AA; Neves JH; Machado-Santelli GM
    J Exp Clin Cancer Res; 2014 Apr; 33(1):37. PubMed ID: 24775603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy.
    Silva R; Vilas-Boas V; Carmo H; Dinis-Oliveira RJ; Carvalho F; de Lourdes Bastos M; Remião F
    Pharmacol Ther; 2015 May; 149():1-123. PubMed ID: 25435018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The allosteric regulatory mechanism of the Escherichia coli MetNI methionine ATP binding cassette (ABC) transporter.
    Yang JG; Rees DC
    J Biol Chem; 2015 Apr; 290(14):9135-40. PubMed ID: 25678706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances.
    Liu L; Liu XD
    Front Pharmacol; 2014; 5():273. PubMed ID: 25540622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter.
    Cole SP
    J Biol Chem; 2014 Nov; 289(45):30880-8. PubMed ID: 25281745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches.
    Wu Q; Yang Z; Nie Y; Shi Y; Fan D
    Cancer Lett; 2014 Jun; 347(2):159-66. PubMed ID: 24657660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural diversity of ABC transporters.
    ter Beek J; Guskov A; Slotboom DJ
    J Gen Physiol; 2014 Apr; 143(4):419-35. PubMed ID: 24638992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATP-binding cassette transporters, atherosclerosis, and inflammation.
    Westerterp M; Bochem AE; Yvan-Charvet L; Murphy AJ; Wang N; Tall AR
    Circ Res; 2014 Jan; 114(1):157-70. PubMed ID: 24385509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.